Clinical Trial Update: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria [Phase 2]

View source ↗

Summary

Phase 2 study evaluating EVO756 in adults with chronic inducible urticaria has completed, reporting on safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inducible Urticaria

Drugs mentioned

• EVO756

Snippet

Sponsor: Evommune, Inc. | Conditions: Chronic Inducible Urticaria | Phase 2 | Status: COMPLETED